A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center